How to Use a Semaglutide Pen | Safe Injection Technique

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide pen administration involves weekly subcutaneous injection using a pre-filled pen device, with doses typically escalating from 0.25 mg to a maintenance range of 1.0–2.4 mg over 16–20 weeks. Correct injection technique, storage protocols, and awareness of individual response factors significantly influence both safety and efficacy outcomes.

Many patients beginning semaglutide focus on mastering the mechanical steps but overlook the clinical context that shapes individual response—including metabolic baseline, gastrointestinal health, and genetic predisposition in key peptide pathways. PlexusDx supports precision-informed treatment by helping patients understand their unique baseline before starting therapy, enabling more productive conversations with prescribing providers about expectations and monitoring.

Understanding the Semaglutide Pen: Device Components and Preparation

The semaglutide pen is a pre-filled, multi-dose injection device containing 1.34 mL of solution (typically 2.4 mg/1.34 mL for maintenance doses). Before first use, pens must be stored in the refrigerator at 2–8°C and warmed to room temperature for 15 minutes to ensure proper medication consistency and reduce injection discomfort.

Each pen includes a replaceable needle, cartridge, dial to select your weekly dose, and an injection button. The dial clicks to confirm dose selection. Inspect the pen for cloudiness or particles before each injection; semaglutide solution should appear clear and colorless. Never use a pen if the medication appears discolored or contains visible particles.

Pre-Injection Checklist: Storage, Inspection, and Preparation Protocol

Proper preparation reduces injection errors and supports consistent dosing schedules. Follow this framework before each weekly dose to verify device integrity and readiness, minimizing the risk of medication waste or inadequate dosing.

Preparation Step	Specific Action
Check expiration date	Confirm pen has not exceeded manufacturer expiration; discard if expired
Inspect medication appearance	Verify solution is clear and colorless; discard if cloudy or contains particles
Confirm storage conditions	Refrigerate unused pens at 2–8°C; remove from refrigerator 15 minutes before injection
Verify correct dose setting	Rotate dial to the dose prescribed by your provider (typically 0.25–2.4 mg weekly)
Attach a fresh needle	Use a new needle for each injection to prevent medication leakage and ensure sterile technique
Clean injection site	Use alcohol swab and allow skin to dry completely before injection to reduce infection risk

Step-by-Step Injection Technique: Site Selection and Administration

Semaglutide is injected subcutaneously (just under the skin) in the abdomen, thigh, or upper arm. The abdomen is preferred by most patients because it offers a larger injection area and consistent absorption. Rotate injection sites within the same body area or between areas weekly to minimize lipodystrophy (thickened or depressed skin) and ensure reliable medication absorption.

After cleaning the site with an alcohol swab and allowing it to dry, pinch the skin to create a fold, insert the needle at a 90-degree angle, and press the injection button until you hear or feel a click, confirming the full dose has been delivered. Maintain pressure for 6 seconds after the click to allow medication to enter tissue. Withdraw the needle slowly and apply gentle pressure with a clean tissue if bleeding occurs.

Safety Considerations, Dose Escalation, and Provider Communication

Semaglutide requires a structured dose escalation schedule supervised by your healthcare provider. Starting doses are intentionally low (0.25 mg weekly) and increase every 1–2 weeks to allow your body to adjust and minimize gastrointestinal side effects. Never increase your dose without explicit provider approval, and do not miss scheduled appointments or blood work that monitors your metabolic response.

Contact your provider immediately if you experience severe abdominal pain, persistent vomiting, signs of dehydration, changes in vision, rapid heartbeat, or signs of injection-site infection (redness, warmth, pus). Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should not use semaglutide. Pregnancy planning should be discussed with your provider at least 2–3 months before attempting conception, as semaglutide is not recommended during pregnancy.

Biomarker Context and Genetic Considerations in Semaglutide Response

Individual variation in semaglutide response is influenced by baseline metabolic markers (fasting glucose, HbA1c, lipid profile) and genetic predisposition in key peptide signaling pathways. Understanding your baseline helps your provider anticipate your likely response range and set realistic expectations for weight loss and metabolic improvement over the 16–20 week titration period.

Genetic variants in the GLP-1 receptor (GLP1R rs6923761), glucagon-like peptide inhibitor receptor (GIPR rs1800437), and appetite-regulation genes (FTO rs9939609, MC4R rs17782313) may provide context for your individual response profile. However, genetics reveal predisposition, not destiny—lifestyle factors, adherence, concurrent medications, and ongoing health changes also shape outcomes. Discussing these genetic and biomarker insights with your provider can support more personalized dose titration and realistic outcome planning.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for how your genetic variants in peptide signaling pathways—including GLP1R, GIPR, FTO, and MC4R—relate to your likely semaglutide response trajectory. This genetic information should be interpreted with a qualified healthcare provider as part of a broader assessment that includes metabolic baselines, medical history, and lifestyle factors.

The Precision Peptide Genetic Test reveals predispositions in peptide genetic pathways, not exact medication response or guarantee of outcomes. Patients with favorable genetic profiles for GLP-1 signaling may experience earlier appetite suppression and metabolic improvements, while others may require longer titration or higher maintenance doses. Genetic testing is one tool to support informed conversations, not a replacement for medical evaluation or dose titration under provider supervision.

Combining your baseline biomarkers (glucose, HbA1c, lipids), genetic predisposition context, and careful injection technique with provider oversight creates a more complete picture for semaglutide success. PlexusDx supports this precision approach by offering compounded semaglutide options ($149/mo) alongside genetic and biomarker assessment, enabling you and your provider to align treatment timing, titration pace, and realistic expectations.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.